MedTrace Logo

Diagnostic Accuracy of Circulating Tumor Cells (CTCs) and Onco-exosome Quantification in the Diagnosis of Pancreatic Cancer - PANC-CTC

NCT03032913 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 52

Last updated 2018-04-10

No results posted yet for this study

Summary

The proposal aims at determining whether liquid biopsy approaches are valid in the diagnosis of pancreatic cancer. Step1 will test 3 CTC isolation methods and analyse by flow cytometry the presence of onco-exosomes in the culture media of pancreatic cell lines. Step 2 will examine the diagnostic accuracy of these blood tumor elements for the diagnosis of cancer of patients with PDAC suspicion or recent diagnosis and their value for disease monitoring.

Conditions

  • Pancreatic Ductal Adenocarcinoma (PDAC)

Interventions

PROCEDURE

Blood samples

Blood samples for both group

PROCEDURE

Portal vein blood sample

Portal vein blood sample during surgery procedure for the Pancreatic Ductal Adenocarcinoma group

Sponsors & Collaborators

  • University Hospital, Bordeaux

    lead OTHER

Principal Investigators

  • Etienne BUSCAIL · University Hospital, Bordeaux

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-02-15
Primary Completion
2017-11-13
Completion
2017-11-13

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03032913 on ClinicalTrials.gov